Related Experiment Videos
Further experience with augmentin in the treatment of skin infections
Abstract:
Thirty-two patients with skin infections were treated with Augmentin, a combination of amoxycillin with the beta-lactamase inhibitor clavulanic acid. These infections were primary skin sepsis (7), infected eczema (11), infected trauma (10) and leg ulcers (4). The majority of cases were caused by amoxycillin-resistant Staphylococcus aureus either alone or in combination with Streptococcus pyogenes. Thirty patients (94%) responded to treatment with only one withdrawal (for side effects). Side effects were limited to nausea (9%) diarrhoea (9%) and rash (3%). No patient with diarrhoea showed evidence of Clostridium difficile toxin production in the stools. Augmentin appears to be a safe, useful, effective antibiotic for the treatment of skin infections in general practice and in hospital. It may prove of particular value when mixed infections of penicillin-resistant staphylococci and Streptococcus pyogenes are present.
Insights
Augmentin, combining amoxycillin and clavulanic acid, effectively treated skin infections in 32 patients. This antibiotic demonstrated a high response rate with minimal side effects, proving valuable for common bacterial skin conditions.
Area of Science:
- Infectious Diseases
- Pharmacology
- Dermatology
Background:
- Skin infections are common in general and hospital practice.
- Amoxycillin resistance in Staphylococcus aureus presents a treatment challenge.
- Mixed infections involving resistant bacteria require effective therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of Augmentin in treating various skin infections.
- To assess the response rate and side effect profile of Augmentin.
- To determine the utility of Augmentin in cases of amoxycillin-resistant bacterial infections.
Main Methods:
- A study involving 32 patients with diverse skin infections.
- Treatment administered with Augmentin (amoxycillin/clavulanic acid).
- Infections included primary skin sepsis, infected eczema, infected trauma, and leg ulcers.
Main Results:
- A high treatment success rate of 94% (30 out of 32 patients) was observed.
- The majority of infections were caused by amoxycillin-resistant Staphylococcus aureus, often with Streptococcus pyogenes.
- Reported side effects were infrequent and mild, including nausea, diarrhea, and rash; no Clostridium difficile toxin was detected.
Conclusions:
- Augmentin is a safe, effective, and useful antibiotic for treating skin infections in both general and hospital settings.
- The combination therapy is particularly valuable for mixed infections involving penicillin-resistant staphylococci and Streptococcus pyogenes.
- The study supports the use of Augmentin in managing common bacterial skin infections effectively.